What's new on giant cell tumor of bone

  • Shinji Tsukamoto
  • , Costantino Errani
  • , Tessa Balach
  • , Tomas Zamora
  • , Eduardo Ortiz-Cruz
  • , Raja Bhaskara Rajasekaran
  • , Raymond Yau
  • , Tao Ji
  • , Israel Pérez-Muñoz
  • , Francisco Linares
  • , Andrea Angelini
  • , Pietro Ruggieri
  • , Joseph Benevenia
  • , Andreas F. Mavrogenis

Producción: Contribución a una revistaArtículo de revisiónrevisión exhaustiva

Resumen

When treating extremities affected by giant cell tumor of bone (GCTB), curettage should be performed to preserve the joint as much as possible in order to obtain a good functional outcome. The local recurrence risk is high following curettage, but new techniques are being developed to reduce local recurrence. We present a review of the literature reporting favorable results of radiofrequency ablation alone in locally recurrent small GCTB. New filling materials are also being developed to prevent non-oncological complications such as arthrosis and fractures. Routine measurement of tartrate-resistant acid phosphatase 5b in serum may be helpful in detecting early instances of local recurrence. For unresectable or metastatic GCTB, there is an urgent need for a new drug that is as effective as denosumab, avoids side effects, and can be administered to pregnant women.

Idioma originalInglés
Número de artículo2
PublicaciónSICOT-J
Volumen12
DOI
EstadoPublicada - 2026

Huella

Profundice en los temas de investigación de 'What's new on giant cell tumor of bone'. En conjunto forman una huella única.

Citar esto